 Secondary Prevention
"Secondary Prevention" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The prevention of recurrences or exacerbations of a disease or complications of its therapy.
| Descriptor ID |
D055502
|
| MeSH Number(s) |
E02.897 N02.421.726.825 N06.850.780.750
|
| Concept/Terms |
Secondary Prevention- Secondary Prevention
- Prevention, Secondary
- Preventions, Secondary
- Secondary Preventions
- Secondary Disease Prevention
- Disease Prevention, Secondary
- Disease Preventions, Secondary
- Prevention, Secondary Disease
- Preventions, Secondary Disease
- Secondary Disease Preventions
Relapse Prevention- Relapse Prevention
- Prevention, Relapse
- Preventions, Relapse
- Relapse Preventions
Early Therapy- Early Therapy
- Early Therapies
- Therapies, Early
- Therapy, Early
|
Below are MeSH descriptors whose meaning is more general than "Secondary Prevention".
Below are MeSH descriptors whose meaning is more specific than "Secondary Prevention".
This graph shows the total number of publications written about "Secondary Prevention" by people in this website by year, and whether "Secondary Prevention" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 | | 2000 | 0 | 3 | 3 | | 2001 | 0 | 3 | 3 | | 2002 | 0 | 5 | 5 | | 2003 | 0 | 3 | 3 | | 2005 | 0 | 2 | 2 | | 2006 | 0 | 5 | 5 | | 2007 | 0 | 8 | 8 | | 2008 | 0 | 5 | 5 | | 2009 | 0 | 3 | 3 | | 2010 | 0 | 13 | 13 | | 2011 | 1 | 5 | 6 | | 2012 | 3 | 6 | 9 | | 2013 | 4 | 7 | 11 | | 2014 | 4 | 9 | 13 | | 2015 | 7 | 6 | 13 | | 2016 | 6 | 15 | 21 | | 2017 | 11 | 10 | 21 | | 2018 | 9 | 10 | 19 | | 2019 | 8 | 10 | 18 | | 2020 | 6 | 9 | 15 | | 2021 | 2 | 2 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Secondary Prevention" by people in Profiles.
-
Jones WS, Mulder H, Wruck LM, Pencina MJ, Kripalani S, Muñoz D, Crenshaw DL, Effron MB, Re RN, Gupta K, Anderson RD, Pepine CJ, Handberg EM, Manning BR, Jain SK, Girotra S, Riley D, DeWalt DA, Whittle J, Goldberg YH, Roger VL, Hess R, Benziger CP, Farrehi P, Zhou L, Ford DE, Haynes K, VanWormer JJ, Knowlton KU, Kraschnewski JL, Polonsky TS, Fintel DJ, Ahmad FS, McClay JC, Campbell JR, Bell DS, Fonarow GC, Bradley SM, Paranjape A, Roe MT, Robertson HR, Curtis LH, Sharlow AG, Berdan LG, Hammill BG, Harris DF, Qualls LG, Marquis-Gravel G, Modrow MF, Marcus GM, Carton TW, Nauman E, Waitman LR, Kho AN, Shenkman EA, McTigue KM, Kaushal R, Masoudi FA, Antman EM, Davidson DR, Edgley K, Merritt JG, Brown LS, Zemon DN, McCormick TE, Alikhaani JD, Gregoire KC, Rothman RL, Harrington RA, Hernandez AF. Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease. N Engl J Med. 2021 05 27; 384(21):1981-1990.
-
Berg DD, Freedman BL, Bonaca MP, Jarolim P, Scirica BM, Goodrich EL, Sabatine MS, Morrow DA. Cardiovascular Biomarkers and Heart Failure Risk in Stable Patients With Atherothrombotic Disease: A Nested Biomarker Study From TRA 2°P-TIMI 50. J Am Heart Assoc. 2021 05 04; 10(9):e018673.
-
Muramoto ML, Hopkins A, Bell M, Allen A, Nair U, Connolly TE. Results of a Feasibility Study of Helpers Stay Quit Training for Smoking Relapse Prevention. Nicotine Tob Res. 2021 03 19; 23(4):711-715.
-
Atar D, Jukema JW, Molemans B, Taub PR, Goto S, Mach F, CerezoOlmos C, Underberg J, Keech A, Tokgözoglu L, Bonaca MP. New cardiovascular prevention guidelines: How to optimally manage dyslipidaemia and cardiovascular risk in 2021 in patients needing secondary prevention? Atherosclerosis. 2021 02; 319:51-61.
-
Hess CN, Bonaca MP. Contemporary Review of Antithrombotic Therapy in Peripheral Artery Disease. Circ Cardiovasc Interv. 2020 10; 13(10):e009584.
-
Kent DM, Saver JL, Ruthazer R, Furlan AJ, Reisman M, Carroll JD, Smalling RW, Jüni P, Mattle HP, Meier B, Thaler DE. Risk of Paradoxical Embolism (RoPE)-Estimated Attributable Fraction Correlates With the Benefit of Patent Foramen Ovale Closure: An Analysis of 3 Trials. Stroke. 2020 10; 51(10):3119-3123.
-
Dobesh PP, Finks SW, Trujillo TC. Dual Antiplatelet Therapy for Long-term Secondary Prevention of Atherosclerotic Cardiovascular Events. Clin Ther. 2020 10; 42(10):2084-2097.
-
Anglemyer A, Moore TH, Parker L, Chambers T, Grady A, Chiu K, Parry M, Wilczynska M, Flemyng E, Bero L. Digital contact tracing technologies in epidemics: a rapid review. Cochrane Database Syst Rev. 2020 08 18; 8:CD013699.
-
Johnson JL, Capin JJ, Arundale AJH, Zarzycki R, Smith AH, Snyder-Mackler L. A Secondary Injury Prevention Program May Decrease Contralateral Anterior Cruciate Ligament Injuries in Female Athletes: 2-Year Injury Rates in the ACL-SPORTS Randomized Controlled Trial. J Orthop Sports Phys Ther. 2020 Sep; 50(9):523-530.
-
Izmirly P, Kim M, Friedman DM, Costedoat-Chalumeau N, Clancy R, Copel JA, Phoon CKL, Cuneo BF, Cohen RE, Robins K, Masson M, Wainwright BJ, Zahr N, Saxena A, Buyon JP. Hydroxychloroquine to Prevent Recurrent Congenital Heart Block in Fetuses of Anti-SSA/Ro-Positive Mothers. J Am Coll Cardiol. 2020 07 21; 76(3):292-302.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|